The USA's Castle Creek Pharmaceuticals has acquired the US rights to the vertigo drug Arlevert (cinnarizine, dimenhydrinate) from family-run German company Hennig Arzneimittel.
Financial terms of the deal were not disclosed.
"Our goal is to expedite the development of Arlevert in the USA by building on the European patient experience of more than 11 million prescribed doses and its track record of effectiveness"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze